A new research study by Hoare et al in PLoS (ungated) projects that, within ten years after countries attain universal access to antiretroviral treatment for AIDS, one fifth of all patients starting treatment will never have a chance to benefit from the least-expensive and least-toxic treatments, because their initial infection will be a drug resistant strain of HIV.
CGD Policy Blogs
Last Monday, CGD posted my working paper entitled, "Prevention Failure: The Ballooning Entitlement Burden of U.S. Global AIDS Treatment Spending and What to Do About It." In response, I've received a number of e-mail comments on various aspects of the paper. A wonder of cyberspace is that I heard from far flung correspondents within hours after the working paper was posted. But the modern technology hasn't overcome the age-old problem of people interpreting an author differently than he intended.
Last week, my colleague April Harding blogged about the recent debates on the most effective strategies for increasing coverage of insecticide-treated nets. She took to task Dr. Arata Kochi, head of WHO's malaria program, for promoting free distribution campaigns rather than the multi-prong strategies recommended by his own organization, among others. Dr.